Business Combination, Aggregate Upfront Payments

No definition available.

Name:	cpix_BusinessCombinationAggregateUpfrontPayments
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Business Combination, Royalties, Range of Payment Over Gross Profits, Percentage

+ References

No definition available.

+ Details

Name:	cpix_BusinessCombinationRoyaltiesRangeofPaymentOverGrossProfitsPercentage
Namespace Prefix:	cpix_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Business Combination, Upfront Payment

+ References

No definition available.

+ Details

Name:	cpix_BusinessCombinationUpfrontPayment
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Payments for Contingent Consideration

+ References

No definition available.

+ Details

Name:	cpix_PaymentsforContingentConsideration
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Recognized Gain (Loss) on Contingent Consideration

+ References

No definition available.

+ Details

Name:	cpix_RecognizedGainLossonContingentConsideration
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue Recognition, Potential Upfront Payment Related to Product Sales

+ References

No definition available.

+ Details

Name:	cpix_RevenueRecognitionPotentialUpfrontPaymentRelatedtoProductSales
Namespace Prefix:	cpix_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_BusinessAcquisitionLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 55
-Paragraph 37
-URI http://asc.fasb.org/extlink&oid=35744172&loc=d3e2207-128464

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

+ Details

Name:	us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Aggregate revenue during the period from the sale of goods in the normal course of business, after deducting returns, allowances and discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(a))
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueGoodsNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1)
-URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688

+ Details

Name:	us-gaap_SalesRevenueNet
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=cpix_AmendedInternationalAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=cpix_PernixTherapeuticsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=cpix_VaprisolMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_BusinessAcquisitionAxis=cpix_OmeclamoxPakMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Vaprisol and Omeclamox-Pak - Narrative (Details) - USD ($)		1 Months Ended	3 Months Ended								12 Months Ended
	Oct. 29, 2013	Apr. 30, 2015	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Feb. 28, 2014
Business Acquisition [Line Items]
Net product revenue											$ 33,013,184	$ 36,683,762	$ 31,100,698
Other revenue, potential upfront payment related to product sales											4,700,000
Net revenues			$ 8,037,488	$ 7,885,048	$ 8,909,741	$ 8,686,774	$ 9,329,412	$ 9,729,047	$ 9,750,168	$ 8,093,244	33,519,051	36,901,871	$ 32,027,462
Amended International Agreement \| Pernix Therapeutics
Business Acquisition [Line Items]
Other revenue, potential upfront payment related to product sales	$ 4,000,000
Vaprisol
Business Acquisition [Line Items]
Upfront payment														$ 2,000,000
Additional upfront payments														$ 2,000,000
Payments for contingent consideration		$ 1,700,000
Gain on contingent consideration											300,000
Acquired contingent liabilities			$ 100,000								100,000
Omeclamox-Pak
Business Acquisition [Line Items]
Additional upfront payments	$ 4,000,000
Net revenues											$ 3,000,000	$ 4,100,000
Omeclamox-Pak \| Minimum
Business Acquisition [Line Items]
Royalty payments based on percentage over gross profits	15.00%
Omeclamox-Pak \| Maximum
Business Acquisition [Line Items]
Royalty payments based on percentage over gross profits	20.00%